Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Multiple Myeloma Physicians

March 10, 2008
Are Avastin and Herceptin complementary treatment choices?
By a GLG Expert Contributor
Analysis of: Herceptin Approved in Japan for Early Treatment in Patients with HER2-Positive Breast Cancer (pharmalive.com)
Herceptin use in the adjuvant and netastatic setting of breast cancer is based on solid clinical data with proven efficacy and rather low and expected toxicity. Avastin use in the metastatic setting of breast cancer is a matter of debate because the efficacy is borderline while the short term and long...
March 7, 2008
American Cancer Society is promoting money in CaCa analysis?
By a GLG Expert Contributor
Analysis of: Two Tests Added to Recommended List to Prevent or Detect Colorectal Cancer (www.nytimes.com)
Virtual Colonoscopy and stool analysis for DNA alterations for colon cancer, are being recommended for screening.
March 6, 2008
Heparin: Unfractionated Heparin, more expensive, less effective and dangerous compared to low molecular weight varieties
By a GLG Expert Contributor
Analysis of: Acute Pulmonary Embolism (content.nejm.org)
     With recent developments in preparation of unfractionated heparins (http://www.nytimes.com/2008/03/06/health/06heparin.html?_r=1&ref=health&oref=slogin) not only are the LMWH varieties more effective as well as cheaper when all of the co factors are included, they...
March 5, 2008
Cholesterol lowering: to advertise or not???
By a GLG Expert Contributor
Analysis of: Drug Pitchmen: Actor, Doctor or Pfizer’s Option (www.nytimes.com)
"Celebrity" advertisements of percription drugs are disingenuous?
March 3, 2008
Teva Camptosar: significance?
By a GLG Expert Contributor
Analysis of: Teva Announces Approval Of Generic Camptosar(R) (www.pipelinereview.com)
Camptosar is being made in Israel I would imagine, and the price differential compared to Pfizer's brand name drug is????
March 3, 2008
"RECORD" would bring record number of approved targted agents for renal cancer
By a GLG Expert Contributor
Analysis of: Novartis Late-State Cancer Trial Is Stopped Early After Meeting Goal (online.wsj.com)
the "Record" trial showed that Novatis' m-Tor inhibitor, everolimus improved progression free survival as compared to placebo in patients with advanced renal cancer who failed several other therapies including Avastin ( Genentech), Nexavar ( Bayer) and/or Sutent ( Pfizer). With The field of targeted...
February 29, 2008
Anesthesia in Colonoscopies: I have an idea for a clinical trial!
By a GLG Expert Contributor
Analysis of: Aetna to Delay Reduced Colonoscopy Coverage (online.wsj.com)
The original plan was to not provide for anesthesia support during the uncomfortable, to say the least, colonoscopys as well as upper endoscopy.
February 28, 2008
Novartis's Everolimus: On it's way to being a competitor for Wyeth's Torisel.
By a GLG Expert Contributor
Analysis of: Novartis Late-State Cancer Trial Is Stopped Early After Meeting Goal (online.wsj.com)
It shares a common mechanism of action with Wyeth's Torisel (mTOR inhibition) and will at least share the market for recurrence after a TK inhibitor fails.
February 27, 2008
Procrit, Aranesp, Epogen: OMG (O my God) now JAMA piles on.
By a GLG Expert Contributor
Analysis of: Higher Risks Found for Anemia Drugs (online.wsj.com)
Meta analysis of multiple papers shows an increased risk of dealth in cancer patients receiving Epo products.
February 26, 2008
CEP-18770 (Cephalon & Cell Therapeutics Europe) an oral proteosome inhibitor: Millenium beware
By a GLG Expert Contributor
Analysis of: CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib (bloodjournal.hematologylibrary.org)
IF this agent works it is ORAL and will certainly be more acceptable to patients than the IV Velcade.

Previous Page : 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 Next231 to 240 of 902

Analytics


Generated at 2009-01-07T13:00:17.563